Inhibitors against VDR are expected to be effective therapeutic agents for bone Paget’s disease, which occurs when the sensitivity of VDR to F0 is abnormally increased, and for hypercalcemia, which is caused by vitamin D overload and other factors. This evidence concerns the gene VDR and hypercalcemia disease.